Abstract

Background: We use a mobile software application (app) to measure for the first time, which fundamental characteristics of raw, natural medical Cannabis flower are associated with changes in perceived insomnia under naturalistic conditions. Methods: Four hundred and nine people with a specified condition of insomnia completed 1056 medical cannabis administration sessions using the Releaf AppTM educational software during which they recorded real-time ratings of self-perceived insomnia severity levels prior to and following consumption, experienced side effects, and product characteristics, including combustion method, cannabis subtypes, and/or major cannabinoid contents of cannabis consumed. Within-user effects of different flower characteristics were modeled using a fixed effects panel regression approach with standard errors clustered at the user level. Results: Releaf AppTM users showed an average symptom severity reduction of −4.5 points on a 0–10 point visual analogue scale (SD = 2.7, d = 2.10, p < 0.001). Use of pipes and vaporizers was associated with greater symptom relief and more positive and context-specific side effects as compared to the use of joints, while vaporization was also associated with lower negative effects. Cannabidiol (CBD) was associated with greater statistically significant symptom relief than tetrahydrocannabinol (THC), but the cannabinoid levels generally were not associated with differential side effects. Flower from C. sativa plants was associated with more negative side effects than flower from C. indica or hybrid plant subtypes. Conclusions: Consumption of medical Cannabis flower is associated with significant improvements in perceived insomnia with differential effectiveness and side effect profiles, depending on the product characteristics.

Highlights

  • 50% of the adult population in the United States (US) experiences sleeping problems [1,2,3,4], with high rates of dissatisfaction over the effectiveness and potential side effects of conventional pharmaceutical sleep aid medications [5]

  • Alone or coupled with other anticholinergics, these medications, in addition to other classes of muscarinic antagonists, may contribute to an increased risk of developing dementia because the effects are cumulative and the body’s production of acetylcholine diminishes with age [12]. These circumstances may make people with insomnia willing to experiment with alternative sleep aid therapies, including medical cannabis, which is commonly used for treating insomnia [13,14,15] and becoming increasingly accessible due to expanding medical and recreational cannabis reformation laws

  • When all product characteristics are included jointly, we find that smoking from a pipe or using a vaporizer is associated with greater symptom relief than smoking joints, and suggestive evidence that higher CBD levels are associated with greater symptom relief even after controlling for other characteristics of the flower consumed

Read more

Summary

Introduction

50% of the adult population in the United States (US) experiences sleeping problems [1,2,3,4], with high rates of dissatisfaction over the effectiveness and potential side effects of conventional pharmaceutical sleep aid medications [5]. Alone or coupled with other anticholinergics, these medications, in addition to other classes of muscarinic antagonists, may contribute to an increased risk of developing dementia because the effects are cumulative and the body’s production of acetylcholine diminishes with age [12]. These circumstances may make people with insomnia willing to experiment with alternative sleep aid therapies, including medical cannabis, which is commonly used for treating insomnia [13,14,15] and becoming increasingly accessible due to expanding medical and recreational cannabis reformation laws.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.